Eevia Health publish investment teaser
THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, SINGAPORE, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.
Eevia Health PLC ("Eevia" or the "Company") is publishing an investment teaser outlining the Company’s strategic reorientation and a rights issue of shares totaling approximately SEK 12.1 million, before deduction of issue costs, as resolved by the board of directors on 17 January 2025 (the "Rights Issue").
Investment teaser
To inform existing shareholders of Eevia Health, as well as other investors and stakeholders, about the Company’s strategic reorientation and turnaround plan, an investment teaser has been prepared. The teaser provides details about the Company, its business, products, strategy, and the Rights Issue. It is attached to this announcement and is also available on Eevia Health’s website at https://eeviahealth.com/investors/.
Investors are advised to review the exemption document published on 27 January 2025.
Timetable for the Rights Issue, all dates occur within 2025
|
28 January – 6 February |
Trading in subscription rights. |
|
28 January – 11 February |
Subscription period for the Rights Issue in Sweden. |
|
29 January – 13 February |
Subscription period for the Rights Issue in Finland. |
|
28 January until the shares subscribed in the Rights Issue are registered with the Finnish Trade Register |
Trading with BTA (paid subscribed share) |
|
17 February |
Estimated date for publication of the outcome from the Rights Issue |
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
Information about Eevia Health Plc
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials, with a focus on gut and related health areas, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
As a pioneering company Eevia is developing biomaterials that may have dramatic impact on human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.